# A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of an Intravenous Infusion of GW328267X in Healthy Volunteers

> **NCT01640990** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 3 (actual)

## Conditions studied

- Lung Injury, Acute

## Interventions

- **DRUG:** Saline
- **DRUG:** GW328267X (total dose of 12mcg)
- **DRUG:** GW328267X (total dose of 40mcg)

## Key facts

- **NCT ID:** NCT01640990
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11-22
- **Primary completion:** 2011-12-09
- **Final completion:** 2011-12-09
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2017-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01640990

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01640990, "A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of an Intravenous Infusion of GW328267X in Healthy Volunteers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01640990. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*